Hepatitis C Virus NS5A Inhibitor

DrugDrug NameDrug Indication
DB09027LedipasvirWhen used in combination with the antiviral medication [DB08934] as the commercially available product Harvoni, ledipasvir is indicated for the treatment of HCV genotypes 1, 4, 5, and 6 with or without [DB00811] depending on the level of liver damage or cirrhosis [FDA Label]. Its use has also proven successful in the treatment of HCV in patients co-infected with HIV [A19627].
DB09102DaclatasvirIndicated for use with sofosbuvir, with or without ribavirin, for the treatment of chronic HCV genotype 1a/b or 3 infection. The dosing regimen of 60mg daclatasvir 60 mg with 400mg sofosbuvir once a day is recommended for both genontypes. Resistance: Reduced susceptibility to daclatasvir was associated with the polymorphisms at NS5A amino acid positions M28, Q30, L31, and Y93 in genotypes 1a, 1b, and 3a patients. NS5A Resistance Testing is recommended for HCV genotype 1a-infected patients with cirrhosis prior to the initiaition of the treatment, as the risk of resistance development is higher in genotype 1a patients.
DB09296OmbitasvirWhen used in combination with [DB09297] and [DB00503] (as the fixed dose product Technivie), Ombitasvir is indicated in combination with [DB00811] for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis [L866]. When used in combination with [DB09297], [DB00503], and [DB09183] (as the fixed dose product Viekira Pak), Ombitasvir is indicated for the treatment of HCV genotype 1b and ,when combined with [DB00811], for the treatment of HCV genotype 1a [FDA Label]
DB11574ElbasvirElbasvir, when used in combination with [DB11575] as the combination product Zepatier, is indicated for use with or without ribavirin for the treatment of chronic HCV genotypes 1 or 4 infection in adults [FDA Label].
DB11613VelpatasvirVelpatasvir is used in combination therapy with other antiviral medications to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptypes 1-6, and to treat HCV and HIV co-infected patients. Depending on the level of cirrhosis or decompensation, combination therapy can also include therapy with [DB00811]. When used in combination with [DB08934] as the combination product Epclusa, Velpatasvir is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, or in combination with [DB00811] if associated with decompensated cirrhosis [FDA Label].
DB13878PibrentasvirIndicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both [FDA Label].
DrugDrug NameTargetType
DB09027LedipasvirNonstructural protein 5Atarget
DB09027LedipasvirP-glycoprotein 1transporter
DB09027LedipasvirATP-binding cassette sub-family G member 2transporter
DB09102DaclatasvirNonstructural protein 5Atarget
DB09102DaclatasvirCytochrome P450 3A5enzyme
DB09102DaclatasvirCytochrome P450 3A4enzyme
DB09102DaclatasvirCytochrome P450 3A43enzyme
DB09102DaclatasvirCytochrome P450 3A7enzyme
DB09102DaclatasvirP-glycoprotein 1transporter
DB09102DaclatasvirSolute carrier organic anion transporter family member 1B1transporter
DB09102DaclatasvirSolute carrier organic anion transporter family member 1B3transporter
DB09102DaclatasvirATP-binding cassette sub-family G member 2transporter
DB09296OmbitasvirNonstructural protein 5Atarget
DB09296OmbitasvirCytochrome P450 2C8enzyme
DB09296OmbitasvirP-glycoprotein 1transporter
DB09296OmbitasvirUDP-glucuronosyltransferase 1-4transporter
DB09296OmbitasvirATP-binding cassette sub-family G member 2transporter
DB11574ElbasvirNonstructural protein 5Atarget
DB11574ElbasvirP-glycoprotein 1transporter
DB11574ElbasvirCytochrome P450 3A4enzyme
DB11574ElbasvirCytochrome P450 3A5enzyme
DB11574ElbasvirCytochrome P450 3A7enzyme
DB11574ElbasvirCytochrome P450 3A43enzyme
DB11613VelpatasvirCytochrome P450 2B6enzyme
DB11613VelpatasvirCytochrome P450 2C8enzyme
DB11613VelpatasvirCytochrome P450 3A4enzyme
DB11613VelpatasvirNonstructural protein 5Atarget
DB11613VelpatasvirP-glycoprotein 1transporter
DB11613VelpatasvirATP-binding cassette sub-family G member 2transporter
DB11613VelpatasvirSolute carrier organic anion transporter family member 1B1transporter
DB11613VelpatasvirSolute carrier organic anion transporter family member 1B3transporter
DB11613VelpatasvirSolute carrier organic anion transporter family member 2B1transporter
DB13878PibrentasvirNonstructural protein 5Atarget
DB13878PibrentasvirCYP3Aenzyme
DB13878PibrentasvirUDP-glucuronosyltransferase 1-1enzyme
DB13878PibrentasvirP-glycoprotein 1transporter
DB13878PibrentasvirATP-binding cassette sub-family G member 2transporter
DB13878PibrentasvirSolute carrier organic anion transporter family member 1B1transporter
DB13878PibrentasvirSolute carrier organic anion transporter family member 1B3transporter